Stepping up Immunotherapy to the next level:
Tapping the Tumor Microenvironment
Our research programs focus on discovering affordable, differentiated, small molecule therapeutics for highly hypoxic tumors where adenosine plays a pivotal role in creating an immunosuppressive and tumor promoting environment.
Discovery of novel antibacterial agents:
Innovative solutions to combat AMR
Our solutions are products of sophisticated technologies with the potential to cover a broad range of priority pathogens in the syndromes of high unmet need, addressing many serious hospital and community infections and combating a broad spectrum of biothreat pathogens.
A key gap in the recently approved drugs, as well as those in late-stage pipeline, is the lack of oral options that cover Gram-Negative and Gram-Positive microbial infections. An intravenous and oral drug product will address the treatment of Gram-Negative and Gram-Positive infections implied in HABP/VABP, CABP, uUTI, cUTI, and other enteric infections.
Modulating the immune system through a small molecule approach offers several unique advantages that are complementary to, and potentially synergistic with, biologic modalities and are poised to significantly extend the scope of immuno-oncology applications and enhance the opportunities for combination with tumour-targeted agents and biologic immunotherapies.